Evidence map›Paper›PMID 19052182›Full record

ArticleJournal of clinical microbiology2009

Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.

Rosendo Jardi, Francisco Rodriguez-Frias, David Tabernero, Maria Homs, Melanie Schaper, Rafael Esteban, Maria Buti

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rosendo JardiDepartments of Biochemistry, Hospital Universitario Vall d'Hebron, Barcelona, Spain. rjardi@vhebron.net
Francisco Rodriguez-Frias
David Tabernero
Maria Homs
Melanie Schaper
Rafael Esteban
Maria Buti
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A line probe assay (INNO-LiPA DR, version 3) for the detection of hepatitis B virus mutations that confer resistance to entecavir therapy was evaluated. The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences.

Indexed as

Antiviral AgentsDNA, ViralGenotypeGuanineHepatitis B virusHumansMolecular Diagnostic TechniquesMutation, MissenseNucleic Acid HybridizationSensitivity and SpecificityAntiviral AgentsDNA, ViralentecavirGuanine

Identifiers

PMID19052182
PMCPMC2643676
OpenAlexW1980514150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.